Orlistat
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1998
- First approval year
- 1998
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Orlistat
- Molecular weight
- 495.75
- Structure (SMILES)
- CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
- alli
- Alli
- Alli (previously orlistat gsk)
- alli previously orlistat gsk
- beacita
- Beacita
- xenical
- Xenical
- 120 mg orlistat
- 60 mg orlistat
- Alli® 60 mg
- l leucine n formyl 1 3 hexyl 4 oxo 2 oxetanyl methyl dodecyl ester 2s 2 alpha r 3 beta
- L-LEUCINE, N-FORMYL-, 1-((3-HEXYL-4-OXO-2-OXETANYL)METHYL)DODECYL ESTER, (2S-(2.ALPHA.(R*),3.BETA.))-
- lipstatin
- Lipstatin
- n formyl l leucine ester with 3s 4s 3 hexyl 4 2s 2 hydroxytridecyl 2 oxetanone
- N-FORMYL-L-LEUCINE, ESTER WITH (3S,4S)-3-HEXYL-4-((2S)-2-HYDROXYTRIDECYL)-2-OXETANONE
- nsc 758881
- NSC-758881
- orlipastat
- Orlipastat
- orlistat
- Orlistat
- Orlistat (Xenical)
- ORLISTAT [EMA EPAR]
- ORLISTAT [HSDB]
- orlistat [INN]
- ORLISTAT [JAN]
- ORLISTAT [MART.]
- ORLISTAT [MI]
- ORLISTAT [ORANGE BOOK]
- ORLISTAT [USAN]
- ORLISTAT [USP MONOGRAPH]
And 31 more, listed on the interactive page.
- ATC classification codes
- A08AB01
Sources for recorded values
- CAS registry numbers
- 96829-58-2
- ChEMBL ID
- CHEMBL175247
- InChIKey
- AHLBNYSZXLDEJQ-FWEHEUNISA-N
- PubChem compound IDs
- 3034010
- RxNorm IDs (RxCUI)
- 37925
- FDA ingredient codes (UNII)
- 95M8R751W8
- Applicant
- CHEPLAPHARM
- Approval date
- 23 Apr 1999
- Application number
- NDA020766
- Status
- Authorised
- Status date
- 29 Jul 1998
- Authorisation date
- 29 Jul 1998
- Approved indications
- Xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) greater or equal to 30 kg/m2, or overweight patients (BMI > 28 kg/m2) with associated risk factors. Treatment with orlistat should be discontinued after 12 weeks if patients have been unable to lose at least 5% of the body weight as measured at the start of therapy.
- Product number
- EMEA/H/C/000154
- Authorisation holder
- CHEPLAPHARM Arzneimittel GmbH
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Obesity
European medicines record
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Over the counter
- Pharmacology name
- orlistat
- Type
- Synthetic organic
- Drug name stem
- -stat
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- pancreatic lipase
- Gene symbol
- PNLIP
- Protein identifier
- P16233
- Median affinity
- 8.9
- Affinity units
- pIC50
- Primary target
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- fatty acid synthase
- Gene symbol
- FASN
- Protein identifier
- P49327
- Median affinity
- 6.55
- Affinity units
- pKi
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- αβ-Hydrolase 12
- Gene symbol
- ABHD12
- Protein identifier
- Q8N2K0
- Median affinity
- 7.1
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- diacylglycerol lipase β
- Gene symbol
- DAGLB
- Protein identifier
- Q8NCG7
- Median affinity
- 7
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- diacylglycerol lipase α
- Gene symbol
- DAGLA
- Protein identifier
- Q9Y4D2
- Median affinity
- 7.2
- Affinity units
- pIC50
- Mechanism
- Gastric lipase inhibitor
- Action type
- Inhibitor
- Target
- Gastric triacylglycerol lipase
- Protein identifier
- P07098
- Mechanism
- Pancreatic lipase inhibitor
- Action type
- Inhibitor
- Target
- Pancreatic triacylglycerol lipase
- Protein identifier
- P16233
- Mechanism
- Gastric lipase inhibitor
- Action type
- Inhibitor
- Target
- Gastric triacylglycerol lipase
- Mechanism
- Pancreatic lipase inhibitor
- Action type
- Inhibitor
- Target
- Pancreatic triacylglycerol lipase
- Action type
- Inhibitor
- Gene symbol
- LIPF
- Protein identifier
- P07098
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Inhibitor
- Gene symbol
- PNLIP
- Protein identifier
- P16233
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Metabolic Syndrome
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000195
- Subject identifier
- D024821
- Condition
- Infertility
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000545
- Subject identifier
- D007246
- Condition
- Polycystic Ovary Syndrome
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000660
- Subject identifier
- D011085
- Condition
- Obesity
- Highest recorded phase
- 4
- Condition identifier
- EFO:0001073
- Subject identifier
- D009765
- Condition
- Hyperlipoproteinemia Type I
- Highest recorded phase
- 2
- Condition identifier
- Orphanet:411
- Subject identifier
- D008072
- Condition identifier
- EFO_0000195
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000195
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000545
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000660
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001073
- Condition identifier
- EFO_0009104
- Condition identifier
- HP_0000789
- Highest recorded phase
- 3
- Condition identifier
- HP_0000822
- Highest recorded phase
- 2
- Condition identifier
- HP_0000855
- Highest recorded phase
- 2
- Condition identifier
- HP_0001397
- Highest recorded phase
- 2
- Condition identifier
- HP_0001513
- Highest recorded phase
- 4
- Condition identifier
- HP_0003418
- Condition identifier
- HP_0010535
- Highest recorded phase
- 2
- Condition identifier
- HP_0025502
- Condition identifier
- HP_0040270
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002775
- Condition identifier
- MONDO_0005010
- Condition identifier
- MONDO_0005061
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005347
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005359
- Condition identifier
- MONDO_0005393
- Condition identifier
- MONDO_0005582
- Condition identifier
- MONDO_0007147
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008487
- Highest recorded phase
- 2
And 6 more, listed on the interactive page.
- Event
- abdominal distension
- Reports
- 28
- Reporting signal score
- 23.1311
- Event
- abdominal pain
- Reports
- 79
- Reporting signal score
- 54.779
- Event
- abdominal pain upper
- Reports
- 49
- Reporting signal score
- 34.3036
- Event
- acute hepatic failure
- Reports
- 32
- Reporting signal score
- 77.073
- Event
- blood uric acid increased
- Reports
- 13
- Reporting signal score
- 30.6695
- Event
- cerebral venous thrombosis
- Reports
- 11
- Reporting signal score
- 32.989
- Event
- cholelithiasis
- Reports
- 34
- Reporting signal score
- 60.6182
- Event
- crystal nephropathy
- Reports
- 12
- Reporting signal score
- 49.6148
- Event
- diarrhoea
- Reports
- 94
- Reporting signal score
- 21.0123
- Event
- diverticulitis
- Reports
- 22
- Reporting signal score
- 30.2251
- Event
- drug interaction
- Reports
- 57
- Reporting signal score
- 28.655
- Event
- faeces pale
- Reports
- 7
- Reporting signal score
- 19.1421
- Event
- flatulence
- Reports
- 26
- Reporting signal score
- 38.6303
- Event
- gallbladder disorder
- Reports
- 12
- Reporting signal score
- 19.014
- Event
- haematochezia
- Reports
- 35
- Reporting signal score
- 48.2226
- Event
- hepatic encephalopathy
- Reports
- 11
- Reporting signal score
- 17.2808
- Event
- hepatic enzyme increased
- Reports
- 29
- Reporting signal score
- 24.4917
- Event
- hepatitis
- Reports
- 19
- Reporting signal score
- 20.0078
- Event
- hyperoxaluria
- Reports
- 12
- Reporting signal score
- 64.4057
- Event
- kidney fibrosis
- Reports
- 11
- Reporting signal score
- 33.2466
- Event
- liver injury
- Reports
- 15
- Reporting signal score
- 19.4713
- Event
- menopausal symptoms
- Reports
- 6
- Reporting signal score
- 17.2971
- Event
- nephropathy
- Reports
- 31
- Reporting signal score
- 91.9738
- Event
- nephrosclerosis
- Reports
- 6
- Reporting signal score
- 20.8647
- Event
- nutritional condition abnormal
- Reports
- 5
- Reporting signal score
- 17.4295
And 10 more, listed on the interactive page.
- NCT00001723
- NCT00115063
- NCT00212199
- NCT00422058
- NCT00752726
- NCT00940628
- NCT01003483
- NCT01035333
- NCT01126970
- NCT01550926
- NCT01755676
- NCT02706067
- NCT04521751
- NCT05579249
- NCT05934110
- NCT00704912
- NCT01675154
- NCT02432209
- NCT02503865
- Dose
- 1 capsule with each meal containing fat
- Route
- Oral
- How often
- Up to 3 capsules daily with meals containing fat
- Do not take more than 3 capsules daily
- Use with a reduced-calorie, low-fat diet and exercise
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 1
- Polar surface area
- 81.7
- Calculated partition coefficient (ALogP)
- 6.88
- Calculated partition coefficient (XLogP)
- 10
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 23
- Heavy atoms
- 35
- Molecular formula
- C29H53NO5
- Monoisotopic mass
- 495.39237379
- Natural product
- Yes
- 61269-460
- 61269-565
- Recorded assays
- 1,631
- Active assays
- 116
- Confirmatory
- Other
- Screening
- Summary
- Enzyme Inhibitors
- Anti-Obesity Agents
- Lipid Regulating Agents
Related records
Trials (64)
- A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss
- A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers
- A Pilot Study of the Efficacy of Alli in the Management of Pre-operative Weight Loss Required for Bariatric Surgery.
- A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary)
- A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
- A Study of Xenical (Orlistat) in Overweight and Obese Adolescents
- A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms
- A Trial With EMP16 in Preparation for Late Phase Studies
- Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder
- Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia
- An RCT of Metformin Vs Orlistat in Obese Anovulatory Women
- Anti-obesity Effects of Dandelion (Taraxacum Officinale L.)
- Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine
- Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding
- Comparison of MAG and Fish Oil Efficacy
- Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome
- Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects
- Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity
- Effect of Orlistat in Body Composition
- Effect of Orlistat on Metabolic and Hormonal Features in Women With Polycystic Ovary Syndrome (PCOS): a Randomized Controlled Clinical Trial
Approved for (1)
In development for (4)
- Familial apolipoprotein C-II deficiency Phase 2
- Infertility disorder Phase 3
- Metabolic syndrome X Phase 1
- Polycystic ovary syndrome Phase 2
Other linked conditions (1)
- Crigler-Najjar syndrome